217 related articles for article (PubMed ID: 33662683)
1. Targeting multiple conformations of SARS-CoV2 Papain-Like Protease for drug repositioning: An in-silico study.
Ismail MI; Ragab HM; Bekhit AA; Ibrahim TM
Comput Biol Med; 2021 Apr; 131():104295. PubMed ID: 33662683
[TBL] [Abstract][Full Text] [Related]
2. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease.
Hajbabaie R; Harper MT; Rahman T
Molecules; 2021 Feb; 26(4):. PubMed ID: 33672721
[TBL] [Abstract][Full Text] [Related]
3. Supporting SARS-CoV-2 Papain-Like Protease Drug Discovery:
Ibrahim TM; Ismail MI; Bauer MR; Bekhit AA; Boeckler FM
Front Chem; 2020; 8():592289. PubMed ID: 33251185
[TBL] [Abstract][Full Text] [Related]
4. Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An
Jamalan M; Barzegari E; Gholami-Borujeni F
J Proteome Res; 2021 Jan; 20(1):1015-1026. PubMed ID: 33350309
[TBL] [Abstract][Full Text] [Related]
5. Repurposing the antibacterial drugs for inhibition of SARS-CoV2-PLpro using molecular docking, MD simulation and binding energy calculation.
Patel R; Prajapati J; Rao P; Rawal RM; Saraf M; Goswami D
Mol Divers; 2022 Aug; 26(4):2189-2209. PubMed ID: 34591234
[TBL] [Abstract][Full Text] [Related]
6. Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2.
Klemm T; Ebert G; Calleja DJ; Allison CC; Richardson LW; Bernardini JP; Lu BG; Kuchel NW; Grohmann C; Shibata Y; Gan ZY; Cooney JP; Doerflinger M; Au AE; Blackmore TR; van der Heden van Noort GJ; Geurink PP; Ovaa H; Newman J; Riboldi-Tunnicliffe A; Czabotar PE; Mitchell JP; Feltham R; Lechtenberg BC; Lowes KN; Dewson G; Pellegrini M; Lessene G; Komander D
EMBO J; 2020 Sep; 39(18):e106275. PubMed ID: 32845033
[TBL] [Abstract][Full Text] [Related]
7. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.
Narayanan A; Narwal M; Majowicz SA; Varricchio C; Toner SA; Ballatore C; Brancale A; Murakami KS; Jose J
Commun Biol; 2022 Feb; 5(1):169. PubMed ID: 35217718
[TBL] [Abstract][Full Text] [Related]
8. Bisindolylmaleimide IX: A novel anti-SARS-CoV2 agent targeting viral main protease 3CLpro demonstrated by virtual screening pipeline and in-vitro validation assays.
Gupta Y; Maciorowski D; Zak SE; Jones KA; Kathayat RS; Azizi SA; Mathur R; Pearce CM; Ilc DJ; Husein H; Herbert AS; Bharti A; Rathi B; Durvasula R; Becker DP; Dickinson BC; Dye JM; Kempaiah P
Methods; 2021 Nov; 195():57-71. PubMed ID: 33453392
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel human USP2 inhibitor and its putative role in treatment of COVID-19 by inhibiting SARS-CoV-2 papain-like (PLpro) protease.
Mirza MU; Ahmad S; Abdullah I; Froeyen M
Comput Biol Chem; 2020 Dec; 89():107376. PubMed ID: 32979815
[TBL] [Abstract][Full Text] [Related]
10. Exploring Cannabinoids as Potential Inhibitors of SARS-CoV-2 Papain-like Protease: Insights from Computational Analysis and Molecular Dynamics Simulations.
Holmes J; Islam SM; Milligan KA
Viruses; 2024 May; 16(6):. PubMed ID: 38932170
[TBL] [Abstract][Full Text] [Related]
11. The SARS-coronavirus papain-like protease: structure, function and inhibition by designed antiviral compounds.
Báez-Santos YM; St John SE; Mesecar AD
Antiviral Res; 2015 Mar; 115():21-38. PubMed ID: 25554382
[TBL] [Abstract][Full Text] [Related]
12. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
[TBL] [Abstract][Full Text] [Related]
13. Protease targeted COVID-19 drug discovery and its challenges: Insight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors.
Amin SA; Banerjee S; Ghosh K; Gayen S; Jha T
Bioorg Med Chem; 2021 Jan; 29():115860. PubMed ID: 33191083
[TBL] [Abstract][Full Text] [Related]
14. Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation.
Rao P; Patel R; Shukla A; Parmar P; Rawal RM; Saraf M; Goswami D
Mol Divers; 2022 Feb; 26(1):309-329. PubMed ID: 33825097
[TBL] [Abstract][Full Text] [Related]
15. Computational investigation of binding of chloroquinone and hydroxychloroquinone against PLPro of SARS-CoV-2.
Patel D; Athar M; Jha PC
J Biomol Struct Dyn; 2022 Apr; 40(7):3071-3081. PubMed ID: 33200683
[TBL] [Abstract][Full Text] [Related]
16. Repurposing clinically approved drugs for COVID-19 treatment targeting SARS-CoV-2 papain-like protease.
Xu Y; Chen K; Pan J; Lei Y; Zhang D; Fang L; Tang J; Chen X; Ma Y; Zheng Y; Zhang B; Zhou Y; Zhan J; Xu W
Int J Biol Macromol; 2021 Oct; 188():137-146. PubMed ID: 34364941
[TBL] [Abstract][Full Text] [Related]
17. Targeting SARS-CoV-2 Main Protease: A Computational Drug Repurposing Study.
Baby K; Maity S; Mehta CH; Suresh A; Nayak UY; Nayak Y
Arch Med Res; 2021 Jan; 52(1):38-47. PubMed ID: 32962867
[TBL] [Abstract][Full Text] [Related]
18. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Papain-Like Protease Potential Inhibitors-In Silico Quantitative Assessment.
Stasiulewicz A; Maksymiuk AW; Nguyen ML; Bełza B; Sulkowska JI
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921228
[TBL] [Abstract][Full Text] [Related]
20.
Huynh T; Cornell W; Luan B
Front Chem; 2020; 8():624163. PubMed ID: 33614597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]